Reuters logo
BRIEF-Cardiome's partner SteadyMed submits U.S. new drug application for TREVYENT
July 3, 2017 / 12:07 PM / 3 months ago

BRIEF-Cardiome's partner SteadyMed submits U.S. new drug application for TREVYENT

July 3 (Reuters) - Cardiome Pharma Corp

* Cardiome’s partner steadymed submits u.s. New drug application for trevyent® for the treatment of pulmonary arterial hypertension

* Cardiome pharma corp - cardiome expects to file trevyent for european medicines agency and health canada approval by end of 2017. Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below